Novo Nordisk's defining moves.
The defining strategic moves at Novo Nordisk — each one explained and grounded in the record.
The Platform · Decision Forks
Novo Nordisk Didn't Pivot to Obesity. It Squeezed One Molecule for a Decade.
The story is that Ozempic's 2017 diabetes approval made Novo stumble onto weight loss. The truth: Novo had already completed a 957-subject Phase 2 obesity trial before it launched its Phase 3 weight-management program. The real fork was never the science. It was whether it could build the factories.
8 min
The Platform Play · Decision Forks
Ozempic Didn't Go Viral and Then Novo Pivoted. The Pivot Came First.
The story is that off-label Ozempic buzz pushed Novo Nordisk into obesity. It's backwards. Wegovy's 2021 approval rested on a dose - semaglutide 2.4 mg - that Novo had been running through dedicated obesity trials for years. The molecule was always the platform.
8 min
The Moat Anatomy · Competitive Advantage
Everyone Thinks Wegovy Is the Moat. It's the Thing the Moat Was Built to Protect.
Novo Nordisk's branded obesity volume share already fell from ~85% to ~70% in a single year, and the semaglutide molecule patent expired in March 2026. So what's left? A 1926 foundation that controls 77% of the votes while owning 28% of the company - and a factory rivals can't replicate on any near timeline.
8 min
The Market-Entry Gambit · Market Entry
Novo Nordisk Didn't Win the Obesity Race. It Was Built So It Couldn't Be Beaten to It.
In 2024 a Danish insulin company briefly became worth more than Denmark's entire GDP. The GLP-1 boom looks like luck. The real story is a 1926 ownership decision that let it spend a century compounding while rivals answered to quarterly shareholders.
8 min